ImmuPharma expect admission to Euronext to take effect from 19 December 2019

ImmuPharma (LON:IMM), a specialist drug discovery and development company, today announced that, further to the announcement of 13 December 2019, that its shares will be admitted to trading on Euronext Growth Brussels under ticker ‘ALIMM’, it has today published the Information Note, as required by the Euronext Growth Market Rules Book and Belgian financial regulations.

The Information Note is available on ImmuPharma’s website www.immupharma.co.uk. Attention is drawn to certain financial information on a period subsequent to that notified in our Interim Results which is included in Parts II and IV of the Information Note which is notifiable under AIM Rule 11. This information is set out in the Appendix below.

Admission to Euronext is expected to take effect from 19 December 2019. This new listing does not affect the trading of ImmuPharma’s shares on AIM, nor is there any intention from the Company to raise additional funds from either AIM or Euronext.

The dual listing on Euronext Growth Brussels aims to further increase the visibility of ImmuPharma’s shares in continental Europe and with European investors, following the Company’s recent deal with Avion Pharmaceuticals, who are now funding an international Phase III trial for the lead programme, Lupuzor™. The investment thesis for ImmuPharma and specifically Lupuzor™ has been repositioned and the Company looks forward to providing further progress updates on the Phase III program with Avion, as well as entering into additional partnerships outside of the US.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. (“MAR”)

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Immupharma Plc

    More articles like this

    Immupharma Plc

    Learning About Lupus

    May is Lupus Awareness Month. It is a disease that is relatively common in the Caribbean yet many of us are unfamiliar with the condition. Lupus is an autoimmune condition that can affect almost every system

    Immupharma Plc

    ImmuPharma Change of Registered Office Address

    ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today announced that with immediate effect, its registered office address has been changed to: One Bartholomew Close, London, EC1A 7BL.

    Immupharma Plc

    ImmuPharma Change of AGM Venue

    ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, today announced that the Company’s Annual General Meeting confirmed for Thursday, 18 June 2020 @ 10.30am, will now be held at: 52 Grosvenor Garden, London SW1W 0AU. The COVID-19

    Immupharma Plc

    Lupus Latest Facts: Causes, Symptoms and Treatments

    Lupus is a relatively rare inflammatory disease. In the US 1.5 million are currently living with the condition. It is an autoimmune disease that can affect various organs including the skin, joints, kidneys, and brain. What

    Immupharma Plc

    Selena Gomez urges fans to join the fight against Lupus

    US singer Selena Gomez has urged her fans across the world to join the fight against Lupus, an autoimmune disease. The disease leads to the body’s immune system becoming hyperactive, attacking normal and healthy tissues. On

    Immupharma Plc

    Understanding Lupus

    Lupus is a chronic (long-term) disease that can cause inflammation and pain in any part of your body. It’s an autoimmune disease, which means that your immune system — the body system that usually fights infections

    Immupharma Plc

    What to know about COVID-19 and lupus

    Lupus is a chronic autoimmune condition in which the immune system attacks its own tissues. People with lupus are at higher risk of infections, and those with lupus who develop COVID-19 may be at higher risk

    Immupharma Plc

    Frequently asked questions: coronavirus (COVID-19) and lupus

    Our Health Educator Network—health-care professionals and lupus specialists who provide individualized answers—have seen their inquires triple in the last week. The following are questions they’ve been frequently asked and their answers. Should I wear a facemask?

    Immupharma Plc

    Are People with Lupus Protected Against COVID-19?

    There is no evidence that taking hydroxychloroquine (Plaquenil) is effective in preventing a person from contracting the coronavirus (COVID-19). People with lupus should follow the guidance of their doctor and the safety guidelines being issued by

    Immupharma Plc

    Dr Miriam Stoppard on Lupus

    Lupus isn’t that common but when it strikes it can be very ­serious, even life-threatening. The story of the singer and ­actress Selena Gomez is a case in point. All lupus sufferers will be grateful to her because